Clinical Trials for Ovarian Cancer

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic CLDN6-positive solid tumors (e.g., ovarian, endometrial, testicular, subsets of NSCLC) receive TORL-1-23 monotherapy, an anti-CLDN6 antibody–drug conjugate delivering MMAE via a cleavable linker, in dose-escalation with tumor-specific expansions. Eligible patients have ECOG 0–1 and adequate organ function; key exclusions include active/symptomatic CNS disease and uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT05103683

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, primary peritoneal, fallopian tube, or other MUC16-positive cancers (including MUC16+ endometrial) after prior platinum therapy and without standard options; a randomized cohort targets platinum‑resistant ovarian cancer after 2–4 prior lines. Investigational therapy is ubamatamab, a MUC16×CD3 T cell–engaging bispecific antibody, given IV as monotherapy or combined with the anti–PD‑1 antibody cemiplimab.

ClinicalTrials.gov ID: NCT03564340

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with PRAME-expressing, recurrent/refractory solid tumors (HLA‑A*02:01+, ECOG 0–1) receive autologous PRAME‑specific TCR‑T therapy (IMA203 or IMA203CD8) after cyclophosphamide/fludarabine lymphodepletion, with low‑dose IL‑2 support and an arm combining IMA203 with nivolumab. IMA203 targets a PRAME peptide via engineered TCR, while IMA203CD8 co‑expresses CD8αβ to enable CD4/CD8 T‑cell tumor killing; nivolumab (PD‑1 inhibitor) is tested for potential synergy.

ClinicalTrials.gov ID: NCT03686124

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/persistent RAS-pathway–mutant ovarian, fallopian tube, primary peritoneal, or endometrial cancers (KRAS/NRAS/HRAS/BRAF/MEK1/MEK2 activating or NF1 loss), measurable and biopsiable, are randomized to selumetinib (MEK1/2 inhibitor) plus olaparib (PARP inhibitor) versus selumetinib alone; ovarian patients must be platinum-ineligible and endometrial patients should have received or been offered immunotherapy (± lenvatinib). No prior MEK inhibitors or progression on PARP allowed; crossover to the combination is permitted at progression from selumetinib monotherapy.

ClinicalTrials.gov ID: NCT05554328

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with high FRα expression (≥75% cells ≥2+ by VENTANA FOLR1), both platinum-sensitive and -resistant (not primary refractory), receive mirvetuximab soravtansine (FRα-targeted antibody–drug conjugate delivering DM4) IV q3w. Patients are randomized to ocular AE prophylaxis with prednisolone acetate eye drops vs brimonidine, with serial ophthalmic assessments; key exclusions include significant ocular disease, >Grade 1 neuropathy, prior FRα therapy, and poor baseline vision.

ClinicalTrials.gov ID: NCT06365853

Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1) receive vismodegib 150 mg PO daily (SMO/Hedgehog inhibitor) plus atezolizumab 1200 mg IV q3w (PD-L1 inhibitor). Single-arm study assessing safety and antitumor activity with RECIST/iRECIST; excludes active autoimmune disease and other major comorbidities.

ClinicalTrials.gov ID: NCT05538091

Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with relapsed non-seminomatous germ-cell tumor (including ovarian GCT) who completed two tandem cycles of high-dose chemotherapy with peripheral-blood stem-cell transplant and have nonrising AFP/hCG are randomized to maintenance oral etoposide 50 mg daily versus observation. Etoposide is a cytotoxic topoisomerase II inhibitor used here as low-dose maintenance to reduce micrometastatic relapse risk.

ClinicalTrials.gov ID: NCT04804007

A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of oral belzutifan, a selective HIF-2α inhibitor, for adults with recurrent or persistent clear cell ovarian carcinoma (≥50% clear cell if mixed) with measurable disease after at least one prior platinum regimen; prior bevacizumab and immunotherapy allowed and treated/stable brain metastases permitted. Patients receive daily belzutifan in 28-day cycles until progression/toxicity, with primary endpoints of ORR and 6-month PFS; class-toxicities include anemia and hypoxia.

ClinicalTrials.gov ID: NCT06677190

A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, platinum‑resistant high‑grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (ECOG 0–1; prior bevacizumab required and PARP inhibitor if BRCA+) receive gemcitabine plus autologous memory‑like NK cell therapy (M‑CENK) with N‑803, an IL‑15 superagonist that expands NK and CD8 T cells. The regimen starts with gemcitabine, then adds repeated M‑CENK infusions and subcutaneous N‑803 from cycle 2 until cell product exhaustion or progression.

ClinicalTrials.gov ID: NCT06710288

A Phase 1/2, Open-label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase 1 and Phase 2) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase 1b) in Patients With Platinum Resistant or Refractory Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with platinum-resistant or -refractory recurrent ovarian, fallopian tube, or primary peritoneal cancer with a lesion amenable to intratumoral/intraperitoneal injection receive the oncolytic adenovirus TILT-123 (igrelimogene litadenorepvec; tumor-selective adenovirus expressing TNFα and IL-2 to inflame TME and recruit/activate T cells) plus pembrolizumab, with a cohort also adding pegylated liposomal doxorubicin. Suitable for ECOG 0–1 patients without active autoimmune disease; Phase 1/1b defines dose and evaluates the triplet, and Phase 2 expands TILT-123 + pembrolizumab.

ClinicalTrials.gov ID: NCT05271318